Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants

Thomas Luger, Mark Boguniewicz, Warner Carr, Michael Cork, Mette Deleuran, Lawrence Eichenfield, Philippe Eigenmann, Regina Fölster-Holst, Carlo Gelmetti, Harald Gollnick, Eckard Hamelmann, Adelaide A. Hebert, Antonella Muraro, Arnold P. Oranje, Amy S. Paller, Carle Paul, Luis Puig, Johannes Ring, Elaine Siegfried, Jonathan M. SpergelGeorg Stingl, Alain Taieb, Antonio Torrelo, Thomas Werfel, Ulrich Wahn

Research output: Contribution to journalReview articleResearchpeer-review

62 Citations (Scopus)


© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. The introduction of the topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10 yr ago was a major breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is approved for second-line use in children (≥2 yr old) and adults with mild-to-moderate AD. The age restriction was emphasized in a boxed warning added by the FDA in January 2006, which also highlights the lack of long-term safety data and the theoretical risk of skin malignancy and lymphoma. Since then, pimecrolimus has been extensively investigated in short- and long-term studies including over 4000 infants (<2 yr old). These studies showed that pimecrolimus effectively treats AD in infants, with sustained improvement with long-term intermittent use. Unlike topical corticosteroids, long-term TCI use does not carry the risks of skin atrophy, impaired epidermal barrier function or enhanced percutaneous absorption, and so is suitable for AD treatment especially in sensitive skin areas. Most importantly, the studies of pimecrolimus in infants provided no evidence for systemic immunosuppression, and a comprehensive body of evidence from clinical studies, post-marketing surveillance and epidemiological investigations does not support potential safety concerns. In conclusion, the authors consider that the labelling restrictions regarding the use of pimecrolimus in infants are no longer justified and recommend that the validity of the boxed warning for TCIs should be reconsidered.
Original languageEnglish
Pages (from-to)306-315
JournalPediatric Allergy and Immunology
Issue number4
Publication statusPublished - 1 Jan 2015


  • Atopic dermatitis
  • Eczema
  • Infants
  • Paediatric
  • Pimecrolimus
  • Safety
  • Tacrolimus
  • Topical calcineurin inhibitors
  • Topical corticosteroids


Dive into the research topics of 'Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants'. Together they form a unique fingerprint.

Cite this